Abstract:Tuberculosis (TB) treatment is time-consuming and is further worsened due to multi-drug resistance and toxicities. Hence, there is a need for the discovery of newer antituberculosis drugs. One of the important and emerging areas of discovering new drugs is by hindering the energy metabolism generator pathway like oxidative phosphorylation (OP) which helps the sustainability of both the replicating and dormant forms of the bacterium in the host. The drugs including Telacebec (Q203) and Bedaquiline target the OP pathway enzymes cytochrome bc1 complex and ATP synthase. However, the tuberculosis bacterium survives even after the inhibition of these enzymes due to the compensatory energy production by Mycobacterium tuberculosis-cytochrome bd oxidase enzyme leading to drug resistance. Additionally, this enzyme helps the survival of the organism in aerobic conditions and in the presence of stress factors including hypoxia conditions, reactive oxygen and nitrogen species. Hence, cytochrome bd oxidase is a promising target for the discovery of novel antitubercular lead candidates. Our work employed computational techniques to design and identify novel imidazopyridines that inhibit cytochrome bd oxidase for developing antitubercular drugs. SwissSimilarity screened structurally similar compounds from the ZINC database and resulted in 989 compounds containing different rings. However, we excluded all the non-bicyclic analogues and this resulted in a library of 824 drug-like candidates as most of the bicyclic compounds showed promising inhibitory action. Further, we considered the versatile nature of amine functionality in terms of synthetic feasibility and improving the antitubercular potency and selected 262 amine-modified derivatives of imidazopyridine (1 to 262). These 262 compounds along with three reported cytochrome bd oxidase inhibitors including amiloride derivative (1a), 2-(Quinolin-4-yloxy)acetamide (2a), and 2-Arylquinolone (3a) were docked against cytochrome bd oxidase (PDB ID: 7NKZ, 2.5 Å). This process identified 255 as the best lead candidate with a docking score of -8.38 than the other 268 compounds and the reported three compounds-1a (-7.47), 2a (-5.70) and 3a (-5.35). These results suggest that the imidazopyridine derivative 255 is a promising lead compound based on its docking score and favorable binding properties indicating strong potential for further development as an anti-TB agent.

Contribution of telacebec to novel drug regimens in a murine tuberculosis model

Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis

In Vitro Interactions Between R207910 And Second-Line Anti-Tb Drugs Or Btz043 Against Mycobacterium Tuberculosis By Microplate Alamar Blue Assay

The kinetics of bedaquiline diffusion in tuberculous cavities opens a window for emergence of resistance.

[Study on the Pharmacodynamic Activity of Combinations with the New Anti-Tuberculosis Drug Pyrifazimine in Vitro and in Vivo in Mouse].

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline

Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis

Bedaquiline: An Insight Into its Clinical Use in Multidrug-Resistant Pulmonary Tuberculosis

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678

A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910

Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis

Structural basis for inhibition of mycobacterial ATP synthase by squaramides and second generation diarylquinolines

Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis

High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against nontuberculous mycobacteria in vitro and in vivo

A Structure‐based Strategy Toward the Development of Novel Candidates for Antimycobacterial Activity: Synthesis, Biological Evaluation, and Docking Study

Innovative Bedaquiline-Based Delivery Systems for Multidrug-Resistant Tuberculosis Treatment

Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis

Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587

Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines

TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice

Novel Imidazopyridine Derivatives Targeting Cytochrome bd Oxidase: A Promising Strategy to Combat Tuberculosis